Glipita M 500

Presentation: Each tablet of Glipita M 500 typically contains 50 mg of sitagliptin and 500 mg of metformin hydrochloride. The tablets are film-coated and are available in blister packs. The appearance of the tablets (shape, color) may vary depending on the manufacturer.

Indications: Glipita M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate. It is used in patients whose blood sugar is not controlled well enough with metformin alone or who are already taking sitagliptin and metformin as separate tablets.

Dosage and Administration: The dosage of Glipita M should be individualized based on the patient's current regimen, effectiveness, and tolerability, not exceeding the maximum recommended daily dose of 100 mg of sitagliptin and 2000 mg of metformin hydrochloride. It is usually taken twice daily with meals to reduce the gastrointestinal side effects associated with metformin.  

• For patients not currently treated with metformin, the starting dose is usually 50 mg sitagliptin/500 mg metformin hydrochloride twice daily, with gradual dose escalation to reduce gastrointestinal side effects.  
• For patients already treated with metformin, the starting dose of Glipita M should provide the sitagliptin dose of 50 mg twice daily, and the metformin dose should be similar to the dose already being taken. Renal function should be assessed before initiating Glipita M and periodically thereafter. Glipita M is contraindicated in patients with an eGFR below 30 mL/min/1.73 m².  

Side Effects: Common side effects may include upper respiratory tract infection, nasopharyngitis, and headache. Due to the metformin component, gastrointestinal side effects such as nausea, vomiting, diarrhea, and abdominal discomfort may also occur, particularly at the start of treatment. Hypoglycemia may occur when Glipita M is used in combination with insulin or sulfonylureas. Pancreatitis has been reported with sitagliptin.  

Precautions: Glipita M is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute metabolic acidosis, including diabetic ketoacidosis, and known hypersensitivity to sitagliptin, metformin, or any of the excipients. It is not recommended for use in patients with type 1 diabetes mellitus. Assess renal function before initiation and monitor periodically. Avoid excessive alcohol intake. Metformin should be temporarily discontinued in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Caution should be exercised in patients with a history of pancreatitis.

Storage: Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.